Search All Tech Briefings


Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available.  Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 130 Results

Title
Intervention Indication Therapeutic Area Year Actions
Lenadogene Nolparvovec (GS-010) for Vision Loss from Leber's Hereditary Optic Neuropathy Due to Mutation of the ND4 Gene Lenadogene nolparvovec (Lumevoq; GS-010) Leber's hereditary optic neuropathy (LHON) Genetic Disorders , Ophthalmology 2017 View  |  Download
Larotrectinib (LOXO-101) for advanced solid cancers [with an NTRK1, NTRK2, or NTRK3 gene fusion] Larotrectinib (LOXO-101; Viktravi; larotrectinib sulfate) Solid tumours Haematological Cancer and Lymphomas , Oncology 2017 View  |  Download
Lanadelumab for prevention of attacks in adults and adolescents with Type I and Type II hereditary angioedema Lanadelumab (SHP643; TAK-743; Takhzyro) Hereditary angioedema (HAE) Genetic Disorders , Immunology 2017 View  |  Download
KTE-C19 for relapsed or refractory mantle cell lymphoma Axicabtagene Ciloleucel (Yescarta; KTE-C19) Mantle cell lymphoma Haematological Cancer and Lymphomas 2017 View  |  Download
Iomab-B for active, relapsed or refractory acute myeloid leukaemia in older patients (aged 55 years and older) I-131-Apamistamab (Iomab-B) Acute myeloid leukaemia (AML) Haematological Cancer and Lymphomas 2017 View  |  Download
Intravenous Doxorubicin Nanoparticles for Advanced Hepatocellular Carcinoma Doxorubicin (Livatag; BA-003; Caelyx; Sarcodoxome; SP-1049C; Resmycin; JNS002; doxorubicin hydrochloride) Hepatocellular carcinoma (HCC) Gastrointestinal Cancer 2017 View  |  Download
IMCgp100 for the Treatment of Advanced or Metastatic Uveal Melanoma IMCgp100 (Tebentafusp) Uveal melanoma Oncology 2017 View  |  Download
Ibrutinib with Venetoclax and Obinutuzumab for the treatment of Chronic Lymphocytic Leukaemia patients with TP53 deletion and/or mutation Obinutuzumab (Gazyvaro; RO5072759; GA101; Afutuzumab) , Venetoclax (Venclyxto; ABT-199; Venclexta; GDC-0199) Chronic lymphocytic leukaemia (CLL) Haematological Cancer and Lymphomas 2017 View  |  Download
Ibrutinib in combination with obinutuzumab for the treatment of chronic lymphocytic leukaemia/small lymphocytic lymphoma in elderly – first line Ibrutinib (Imbruvica) , Obinutuzumab (Gazyvaro; RO5072759; GA101; Afutuzumab) Chronic lymphocytic leukaemia (CLL) , Small lymphocytic lymphoma (SLL) Haematological Cancer and Lymphomas 2017 View  |  Download
Ibrutinib for the treatment of relapsed or refractory follicular lymphoma Ibrutinib (Imbruvica) Follicular lymphoma Haematological Cancer and Lymphomas 2017 View  |  Download
1 2 6 7 8 9 10 12 13
Medicines
Medicine Industry's Gateway to NICE
Support for Industry
Outputs & Publications